- Home
- FOA vs MRSN Comparison
FOA vs MRSN Comparison
Compare FOA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- MRSN
- Stock Information
- Founded
- FOA 2013
- MRSN 2001
- Country
- FOA United States
- MRSN United States
- Employees
- FOA N/A
- MRSN N/A
- Industry
- FOA Finance Companies
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- MRSN Health Care
- Exchange
- FOA Nasdaq
- MRSN Nasdaq
- Market Cap
- FOA 231.1M
- MRSN 230.0M
- IPO Year
- FOA N/A
- MRSN 2017
- Fundamental
- Price
- FOA $20.77
- MRSN $2.02
- Analyst Decision
- FOA Hold
- MRSN Buy
- Analyst Count
- FOA 1
- MRSN 6
- Target Price
- FOA $24.00
- MRSN $6.00
- AVG Volume (30 Days)
- FOA 100.0K
- MRSN 1.2M
- Earning Date
- FOA 11-06-2024
- MRSN 11-13-2024
- Dividend Yield
- FOA N/A
- MRSN N/A
- EPS Growth
- FOA N/A
- MRSN N/A
- EPS
- FOA 10.89
- MRSN N/A
- Revenue
- FOA $719,526,000.00
- MRSN $34,837,000.00
- Revenue This Year
- FOA N/A
- MRSN N/A
- Revenue Next Year
- FOA N/A
- MRSN $7.15
- P/E Ratio
- FOA $1.90
- MRSN N/A
- Revenue Growth
- FOA 3011.46
- MRSN N/A
- 52 Week Low
- FOA $4.10
- MRSN $1.22
- 52 Week High
- FOA $27.89
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- FOA 59.40
- MRSN 50.80
- Support Level
- FOA $18.21
- MRSN $1.98
- Resistance Level
- FOA $27.89
- MRSN $2.35
- Average True Range (ATR)
- FOA 3.78
- MRSN 0.26
- MACD
- FOA 0.41
- MRSN -0.02
- Stochastic Oscillator
- FOA 54.94
- MRSN 38.35
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.